Clarient Breathes Life Into Lung Cancer Biz With Applied Genomics Buy
This article was originally published in The Gray Sheet
Executive Summary
Clarient is expanding its lung cancer business and gaining a pipeline of immunohistochemistry tests for lung, breast and ovarian cancers with its $17.6 million acquisition of Applied Genomics